In A First, Kerala Drugs Control Dept Files Complaint Against Divya Pharmacy In Kozhikode Court

Kozhikode: After the Supreme Court, yoga and ayurveda guru Baba Ramdev is set to face legal proceedings in Kerala over alleged misleading drug promotions. The Kerala government’s drugs control department is the first such state agency to file a case to prosecute Baba Ramdev and Divya Pharmacy he founded. He has been named third accused in the case, after the pharmacy and Acharya Balkrishna, chairman of Patanjali Ayurved. If convicted the duo could face a jail term of up to six months and a fine.

In its case, filed before the Judicial First Class Magistrate Court IV in Kozhikode, the department said that Divya Pharmacy had advertised pharmaceutical products that claimed to cure sexual impotence and diabetes. These are among the 54 diseases for which cure should not be advertised, under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

Though the pharmacy has been repeatedly accused of violating drug laws, it eluded prosecution due to difficulties in filing cases. This time, however, the drugs regulator was emboldened by the Supreme Court’s intervention. Drugs controller Dr K Sujith Kumar ordered a statewide combing operation, involving 40 inspectors, to dig up violations. In Kozhikode region alone, 20 instances of violations were found, which forms the basis of the department case.

Shaji Varghese, the assistant drugs controller, sent a special team to Delhi to trace the people responsible for the advertisements. The case was initiated based on a complaint filed by Dr Babu K V, a health activist from Kannur.

“Repeated advertising by Patanjali, which involved even urging patients to stop taking insulin for type 1 diabetes and switch over to their products, can lead to a major public health crisis, with parents stopping insulin for children. I am certain the decisive intervention of the Supreme Court and prosecution by Kerala drug authorities will put an end to ongoing illegal advertising by Patanjali and other ayurveda companies,” said Dr Babu, who also played a decisive role in the case against Baba Ramdev in the SC.

Since 2022, he has filed over 100 RTI applications and complaints to halt alleged illegal drug promotions by Divya Pharmacy.

The Kerala government’s drugs control department is the first state agency to file a case to prosecute Baba Ramdev and Divya Pharmacy he founded. He has been named third accused in the case, after the pharmacy and Acharya Balkrishna, chairman of Patanjali Ayurved.

Related Posts

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

New Delhi: Serious legal gaps in the Drugs and Cosmetics Act, 1940, combined with acute shortages of manpower and infrastructure, continue to impede the Central Drugs Standard Control Organisation (CDSCO)…

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna: In a significant ruling that could have far-reaching implications for NDPS drug-related prosecutions involving common pharmaceutical compounds, the Patna High Court has held that Phenothiazine and Promethazine do not…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines